# OnCo record idea-tr1-extended-interval-checkpoint-dosing (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-tr1-extended-interval-checkpoint-dosing/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-tr1-extended-interval-checkpoint-dosing" ;
  schema:name "Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable"@en ;
  schema:description "Immunotherapy antibodies stay active in the body for weeks, yet are often given every two or three weeks. After a few months, spacing doses out to every two or three months might work as well, with fewer hospital visits and much lower cost."@en ;
  schema:url <https://onco.cc/ideas/idea-tr1-extended-interval-checkpoint-dosing/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/atezolizumab/> ;
  onco:trials <https://onco.cc/trials/checkmate-227/>, <https://onco.cc/trials/checkmate-915/>, <https://onco.cc/trials/fianlimab-phase3-melanoma/>, <https://onco.cc/trials/keynote-042/>, <https://onco.cc/trials/relativity-098/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-dose-optimisation/>, <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-topalian-anti-pd1-nejm-2012/>, <https://onco.cc/key-papers/paper-keynote-024-nejm-2016/>, <https://onco.cc/key-papers/paper-keynote-010-lancet-2016/> .
